Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Crenolanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 known ✓ | P36888 | 5/20 | 0.85 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.85 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 0.85 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.85 |
| ▸ | RET | P07949 | 2/20 | 0.85 |
| ▸ | GAK | O14976 | 1/20 | 0.85 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.85 |
| ▸ | ULK1 | O75385 | 1/20 | 0.85 |
| ▸ | STK10 | O94804 | 1/20 | 0.85 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.85 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.85 |
| ▸ | LATS1 | O95835 | 1/20 | 0.85 |
| ▸ | PAK4 | O96013 | 1/20 | 0.85 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.85 |
| ▸ | LCK | P06239 | 1/20 | 0.85 |
| ▸ | CDK1 | P06493 | 1/20 | 0.85 |
| ▸ | APRT | P07741 | 1/20 | 0.85 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.85 |
| ▸ | NQO2 | P16083 | 1/20 | 0.85 |
| ▸ | FECH | P22830 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Crenolanib SCHEMBL29361948 | 1.00 | FLT3 (0.85) | FLT3IRAK4RETGAKRIPK2 | |
| Crenolanib SCHEMBL4681285 | 1.00 | FLT3 (0.85) | FLT3IRAK4RETGAKRIPK2 | |
| Crenolanib SCHEMBL2730601 | 0.92 | FLT3 (1.00) | FLT3IRAK4RETGAKRIPK2 | |
| Crenolanib SCHEMBL29350134 | 0.92 | FLT3 (1.00) | FLT3IRAK4RETGAKRIPK2 | |
| Crenolanib SCHEMBL30002138 | 0.92 | FLT3 (1.00) | FLT3IRAK4RETGAKRIPK2 | |
| Crenolanib SCHEMBL29352568 | 0.92 | FLT3 (1.00) | FLT3IRAK4RETGAKRIPK2 | |
| SCHEMBL24139877 | 0.88 | FLT3 (0.72) | FLT3IRAK4RETGAKRIPK2 | |
| SCHEMBL4681289 | 0.86 | FLT3 (0.71) | FLT3IRAK4RETGAKRIPK2 | |
| SCHEMBL24556935 | 0.86 | FLT3 (0.69) | FLT3IRAK4RETGAKRIPK2 | |
| SCHEMBL25862336 | 0.86 | FLT3 (0.68) | FLT3IRAK4RETGAKRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486256-B2 | Crystal forms of crenolanib and methods of use thereof | AROG PHARMACEUTICALS, INC. (US) | 2025-12-02 | — | — | US | claimed |
| CN-113956245-A | Crystalline forms of clainib and methods of use thereof | 安罗格制药有限责任公司 | 2022-01-21 | — | — | CN | claimed |
| US-12486256-B2 | Crystal forms of crenolanib and methods of use thereof | AROG PHARMACEUTICALS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-12486256-B2 | Crystal forms of crenolanib and methods of use thereof | AROG PHARMACEUTICALS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20230339918-A1 | CRYSTAL FORMS OF CRENOLANIB AND METHODS OF USE THEREOF | AROG PHARMACEUTICALS, INC. | 2023-10-26 | — | — | US | disclosed |
| CN-113956245-A | Crystalline forms of clainib and methods of use thereof | 安罗格制药有限责任公司 | 2022-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486256-B2 | Crystal forms of crenolanib and methods of use thereof | CYP1B1, CYP4B1, PDE8B | FLT3 186/4885PDGFRB 71/4885PDGFRA 446/4885 |
| US-20230339918-A1 | CRYSTAL FORMS OF CRENOLANIB AND METHODS OF USE THEREOF | CYP1B1, CYP4B1, PDE8B | FLT3 185/4885PDGFRB 72/4885PDGFRA 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.